# A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

> **NCT00938652** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 519 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** gemcitabine/carboplatin
- **DRUG:** Iniparib

## Key facts

- **NCT ID:** NCT00938652
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2011-01
- **Final completion:** 2012-02
- **Target enrollment:** 519 (ACTUAL)
- **Last updated:** 2013-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00938652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00938652, "A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00938652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*